Drug Development & Gene and Cell Therapy Expert Witness

Drug Development & Gene and Cell Therapy Expert Witness

Drug Development & Gene and Cell Therapy | E-621884

Expert Qualifications

This highly-qualified expert has 14 years of experience in the field of biopharmaceutical development, having earned her BS in biology from the University of North Carolina and her PhD in genetics from the University of California at San Francisco. Her work focuses on drug development with a particular focus on gene and cell therapies, including those with the following elements: AAV, Adenovirus, CRISPR, Zfn, Endonuclease, CAR-T, mRNA, LNP, Lentivirus, HSPC. She has worked in positions such as principal consultant for Halloran Consulting Group, the founder and CEO of Tremont Therapeutics, the senior director of Shire PLC, and the executive director of CRISPR Therapeutics. She is also involved in research in her field as an author of several scientific articles. This expert currently works as the principal at a drug development consulting company in Massachusetts.

Bio Snapshot

Location: MA

BS, Biology, University of North Carolina

PhD, Genetics, University of California, San Francisco

Former, Scientific Education Manager, NIBR Education Office, Novartis Institutes for BioMedical Research

Former, Program Manager, NIBR Drug Discovery Incubator, Novartis Institutes for BioMedical Research

Former, Program Manager, Business Planning and Program Management, Alnylam Pharmaceuticals

Former, Founder and CEO, Tremont Therapeutics

Former, Principal Consultant, Halloran Consulting Group

Former, Early Development Program Leader, Shire PLC

Former, Senior Director, Shire PLC

Former, Program Leader, Hemoglobinopathy, CRISPR Therapeutics

Former, Executive Director, CRISPR Therapeutics

Current, Principal, a drug development consulting company in MA

Related Experts

image

Send a message to this Drug Development & Gene and Cell Therapy Expert Witness